Is a Biosimilar (Generic) Top Cancer Drug for You?
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 276Are Volcano Shareholders Getting Enough in the Buyout?
Guided therapy tools maker Volcano has announced that it has entered into a definitive agreement to be acquired by Koninklijke Philips.
43 Million Americans Have Unpaid Medical Bills
According to a new study from the Consumer Financial Protection Bureau, 42.9 million Americans have unpaid medical bills.
What a Generic Celebrex Means for Pfizer and for Actavis
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in America.
Are Investors Signaling Optimism in Biotechs Through Short Interest?
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Norway’s Oil Decline Accelerating
New oil projects are being scrapped in Norway amid falling production and low oil prices.
Bellicum Sets Pricing Terms for IPO
Bellicum Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.
After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?
SunTrust Robinson Humphrey analysts say in a research note that Achaogen and Cempra could be in play as acquisition targets.
Merck, Cubist Agree to $9.5 Billion Acquisition
Merck will acquire Cubist for $102 a share, or, about $9.5 billion, including $1.1 billion in Cubist’s net debt and other items.
MannKind Sees More Insider Selling
MannKind saw its shares trading lower on Thursday. The culprit may simply be insiders selling more shares.
Array BioPharma: When Losing a Partnership Is Good News
Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer drug binimetinib.
Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015
Credit Suisse has released a biotech research report that has their top picks for upside potential in the biotech segment for 2015.
Are Avanir Shareholders Getting Enough in the Buyout?
Avanir Pharmaceuticals announced that it has entered into a definitive agreement with Otsuka Pharmaceutical for a $17.00 per share buyout.
5 Critical Biotech Drug Dates and Events for December
At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.
Regenerative Medicine Company on Track for IPO This Week
The week after the Thanksgiving holiday stacks up to be another quiet one on the IPO front.